A 48-year-old man with a 15-year history of intravenous drug use presents to the clinic with fatigue, jaundice, and right upper quadrant pain. He reports a previous episode of acute hepatitis 12 years ago. On examination, he has hepatomegaly, splenomegaly, and stigmata of chronic liver disease (spider angiomata, palmar erythema). Liver function tests show ALT 120 U/L, AST 180 U/L, bilirubin 3.8 mg/dL, albumin 2.8 g/dL, and INR 1.8. Serological testing reveals: HBsAg positive, anti-HBc positive, anti-HBe positive, HBeAg negative, anti-HCV positive (confirmed by HCV RNA PCR), and anti-HDV positive with detectable HDV RNA. What is the primary driver of his advanced liver disease?

Explanation

## Diagnosis: HBV/HDV Coinfection with Advanced Cirrhosis ### Serological Interpretation **Key Point:** The presence of **HBsAg positive**, **anti-HBc positive**, **anti-HDV positive with detectable HDV RNA** confirms chronic HBV infection with active HDV superinfection. ### HDV: The "Defective" Virus with Devastating Impact **High-Yield:** Hepatitis D virus (HDV) is a unique defective RNA virus that requires HBsAg for replication. It exists in two epidemiological patterns: | Feature | HBV Alone | HBV + HDV Coinfection | HBV + HDV Superinfection | |---------|-----------|----------------------|------------------------| | **Acquisition** | Single exposure | Simultaneous HBV/HDV | HDV acquired after chronic HBV | | **Severity** | Mild-moderate | Severe acute hepatitis | Acute worsening of chronic disease | | **Cirrhosis risk** | 5–10% over 20 yrs | 70% within 5–10 yrs | Rapid progression to cirrhosis | | **Fibrosis rate** | Slow (10–30 yrs) | Accelerated (5–10 yrs) | **Accelerated** | | **HBsAg required?** | N/A | Yes (obligate) | Yes (obligate) | **Clinical Pearl:** This patient has **HBV/HDV superinfection** (acquired HDV after chronic HBV), which is clinically more severe than HBV/HDV coinfection. The presence of detectable HDV RNA indicates active viral replication and is the primary driver of rapid cirrhosis progression. ### Why HDV Is the Primary Driver Here 1. **Obligate dependence:** HDV cannot replicate without HBsAg; it is a defective virus that uses HBsAg as its envelope antigen. 2. **Accelerated fibrosis:** HBV/HDV coinfection causes cirrhosis in 70% of patients within 5–10 years, compared to 5–10% of HBV-monoinfected patients over 20 years. 3. **Detectable HDV RNA:** Active viral replication (HDV RNA positive) indicates ongoing hepatocyte injury and immune-mediated inflammation. 4. **Clinical evidence:** The patient's advanced cirrhosis (low albumin, elevated INR, splenomegaly, ascites risk) at age 48 with 12 years of chronic disease is consistent with HDV-accelerated progression. ### Serological Markers Explained - **HBsAg positive:** Chronic HBV infection - **Anti-HBc positive:** Past or ongoing HBV exposure (marker of chronicity) - **HBeAg negative, anti-HBe positive:** Low HBV replication ("inactive carrier" phase of HBV alone, but HDV reactivates HBV replication) - **Anti-HDV positive + HDV RNA positive:** Active HDV infection - **Anti-HCV positive + HCV RNA positive:** Concurrent HCV infection (triple infection) **Mnemonic: HBV/HDV Progression — "D Defies Delay"** - **D**efective virus (HDV needs HBsAg) - **D**evastating (70% cirrhosis in 5–10 yrs) - **D**elays nothing (accelerates fibrosis) ### Why HCV Is Not the Primary Driver Here While HCV is the most common cause of cirrhosis globally, this patient has **detectable HDV RNA with active replication**, which is a more potent accelerator of fibrosis than HCV alone. In HBV/HDV coinfection, HDV is the dominant pathogenic force. [cite:Harrison 21e Ch 370; Robbins 10e Ch 18]